CO119 Indirect Treatment Comparison and Cost-Minimization Analysis between Riociguat and Selexipag to WHO Functional Class III Pulmonary Arterial Hipertension (PAH) Patients
Abstract
Authors
R. Saad D. Foli G. Britto C. Roubik R. Mattar G. Roncato